Sugi Predict

Sugi Predict / Compounds / SCHEMBL3244083

SCHEMBL3244083

SCHEMBL3244083

CN(C[C@@H]1CCCNC1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.38
▸ CPN1 P15169 1/20 0.38
▸ CPB2 Q96IY4 1/20 0.38
▸ KMT2A Q03164 2/20 0.35
▸ EPHX1 P07099 1/20 0.35
▸ GPR88 Q9GZN0 1/20 0.34
▸ SLC6A4 P31645 4/20 0.34
▸ HTR2C P28335 3/20 0.34
▸ SLC6A1 P30531 4/20 0.33
▸ SLC6A11 P48066 3/20 0.33
▸ SLC6A13 Q9NSD5 3/20 0.33
▸ CHRNB2 P17787 2/20 0.33
▸ CHRNB4 P30926 2/20 0.33
▸ CHRNA3 P32297 2/20 0.33
▸ CHRNA4 P43681 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ NAAA Q02083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359460 1.00 USP30 (0.38) USP30CPN1CPB2KMT2AEPHX1
SCHEMBL3253450 1.00 USP30 (0.38) USP30CPN1CPB2KMT2AEPHX1
SCHEMBL15363216 0.91 USP30 (0.45) USP30SLC6A4HTR2CSLC6A1SLC6A11
SCHEMBL3699616 0.91 USP30 (0.45) USP30SLC6A4HTR2CSLC6A1SLC6A11
SCHEMBL15363207 0.91 USP30 (0.45) USP30SLC6A4HTR2CSLC6A1SLC6A11
SCHEMBL13627183 0.85 SPR (0.34) USP30KMT2ASLC6A4HTR2CCYP2D6
SCHEMBL3301278 0.84 CPN1 (0.37) CPN1CPB2KMT2AEPHX1GPR88
SCHEMBL24438464 0.83 ALOX5 (0.39) EPHX1SLC6A4HTR2CHTR2A
SCHEMBL18105275 0.83 CPN1 (0.34) USP30CPN1CPB2KMT2AEPHX1
SCHEMBL803364 0.82 USP30 (0.36) USP30CPN1CPB2SLC6A4HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-05-26 — — US disclosed
WO-2024253416-A1 PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-12-12 — — WO disclosed
CN-117510497-A DGK zeta inhibitors 山东轩竹医药科技有限公司 2024-02-06 — — CN disclosed
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 — — US disclosed
EP-4051664-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS Cancer Research Technology Limited (GB) 2022-09-07 — — EP disclosed
WO-2021084265-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 — — WO disclosed
WO-2021084264-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 — — WO disclosed
EP-3311813-B1 THERAPEUTIC ISOXAZOLE COMPOUNDS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-08-07 — — EP disclosed
EP-3311813-B1 THERAPEUTIC ISOXAZOLE COMPOUNDS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-08-07 — — EP disclosed
US-10053467-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2018-08-21 — — US disclosed
US-20120202786-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2012-08-09 — — US disclosed
US-8222243-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD (KY) 2012-07-17 — — US disclosed
US-8222243-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD (KY) 2012-07-17 — — US disclosed
US-8222243-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD (KY) 2012-07-17 — — US disclosed
EP-2182809-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS Helicon Therapeutics, Inc. (US) 2010-05-12 — — EP disclosed
US-20090062252-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 — — US disclosed
US-20090062252-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 — — US disclosed
WO-2009029632-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 — — WO disclosed
WO-2009029632-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 — — WO disclosed
US-20090062252-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053467-B2 Therapeutic isoxazole compounds MAOB, MAOA, XDH USP30 3376/4885CPN1 1435/4885CPB2 776/4885
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors SIK2, SIK1, SIK3 USP30 4398/4885CPN1 3374/4885CPB2 2775/4885
US-20120202786-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS MAOB, MAOA, XDH USP30 3376/4885CPN1 1435/4885CPB2 776/4885
US-20090062252-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS MAOB, MAOA, XDH USP30 3376/4885CPN1 1435/4885CPB2 776/4885
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS SIK2, SIK3, SIK1 USP30 3415/4885CPN1 4579/4885CPB2 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.